leadf
logo-loader
viewJohnson & Johnson

Johnson & Johnson starts new UK COVID-19 vaccine trial with 6,000 participants

The pharma giant is looking to see whether two doses can protect patients for longer

Johnson & Johnson - Johnson & Johnson starts new UK COVID-19 vaccine trial with 6,000 participants

Johnson & Johnson (NYSE:JNJ) has started a new late-stage study of its COVID-19 vaccine candidate which will enrol 6,000 people in the UK.

In addition to the ongoing single-dose study, the company’s Belgian arm Janssen is embarking in a trial to assess the efficacy of two doses, with the two assessments running in parallel.

READ: Which Covid vaccine candidates are competing against Pfizer?

The studies follow positive interim results from an ongoing phase 1/2a clinical trials, which showed that the jab induced an immune response and was generally well-tolerated when injected once.

The pharma giant is looking to see whether two doses can protect patients for longer.

It will involve up to 30,000 participants worldwide in Belgium, Colombia, France, Germany, the Philippines, South Africa, Spain, the US, as well as the UK.

Quick facts: Johnson & Johnson

Price: 162.78 USD

NYSE:JNJ
Market: NYSE
Market Cap: $428.53 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Tirupati Graphite presents progress at their Graphene and Mintech Research...

Tirupati Graphite PLC's (LON:TGR) CEO Shishir Poddar talks to Proactive London about the progress being made at their research centre, the Tirupati Graphene and Mintech Research Centre (TGMRC) in India. Poddar discusses the drive and innovation of his team which is working together to enhance...

9 minutes ago

2 min read